Share This Article:

Predictors of survival among 60 patients with tissue proven primary cardiac amyloidosis

Abstract Full-Text HTML Download Download as PDF (Size:335KB) PP. 23-29
DOI: 10.4236/ojcd.2013.32006    3,166 Downloads   5,056 Views  

ABSTRACT

Background: Cardiovascular involvement among patients with primary systemic amyloidosis (AL) is common and predicts poor prognosis. Different parameters have been used to predict outcome. We studied the prognostic significance of clinical, ECG and echocardiographic parameters of 60 patients with tissue proven primary cardiac amyloidosis. Method and Results: Records of 60 patients with primary amyloidosis and cardiac involvement documented by endomyocardial tissue biopsy were retrospectively evaluated. Patients mean age was 57.9 ± 10.2 years. 71.6% were male and 86.6% Caucasian. Patients’ median survival was 12.2 ± 4.4 months with only 50% of patients survived for more than 1 year. 60% of patients had CHF (NYHA II-IV). CHF (NYHA II-IV), IVS, LVPW and LVEF were significant on univariate survival analysis (p < 0.05). On multivariate analysis only CHF (p = 0.027, HR 3.04 [95% CI: 1.1 - 8.1]) and IVS < 1.5 cm(p = 0.012, HR: 3.51 [95% CI: 1.3 - 9.3]) were predictors of survival. Patients with CHF had a median survival of 7.58 ± 1.74 months contrary to those without CHF who had a median survival of 31.2 ± 11.41 months. Patients with IVS ≥1.5 cmhad a median survival of 7.0 ± 1.1 months, contrary to those with an IVS <1.5 cmwho had a median survival of 31.9 ± 12.4 months. Conclusion: In patients with primary amyloidosis and cardiac involvement, length of survival is strongly associated with CHF (NYHA II-IV) and IVS compared to other electrographic and echocardiographic parameters

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Suradi, H. , Bitar, A. , Benson, M. and Das, M. (2013) Predictors of survival among 60 patients with tissue proven primary cardiac amyloidosis. Open Journal of Clinical Diagnostics, 3, 23-29. doi: 10.4236/ojcd.2013.32006.

References

[1] Falk, R.H. (2005) Diagnosis and management of the cardiac amyloidoses. Circulation, 112, 2047-2060. doi:10.1161/CIRCULATIONAHA.104.489187
[2] Falk, R.H., Comenzo, R.L. and Skinner, M. (1997) The systemic amyloidoses. The New England Journal of Medicine, 337, 898-909. doi:10.1056/NEJM199709253371306
[3] Kyle, R.A. (1995) Amyloidosis. Circulation, 91, 1269-1271. doi:10.1161/01.CIR.91.4.1269
[4] Chew, C., Ziady, G.M., Raphael, M.J. and Oakley, C.M. (1975) The functional defect in amyloid heart disease. The “stiff heart” syndrome. American Journal of Cardiology, 36, 438-444. doi:10.1016/0002-9149(75)90891-7
[5] Dubrey, S.W., Cha, K., Anderson, J., Chamarthi, B., Reisinger, J., Skinner, M. and Falk, R. H. (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Qurom Journal Manager, 91, 141-157. doi:10.1093/qjmed/91.2.141
[6] Mueller, P.S., Edwards, W.D. and Gertz, M.A. (2000) Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. American Journal of Medicine, 109, 181-188. doi:10.1016/S0002-9343(00)00471-X
[7] Kyle, R.A. and Gertz, M.A. (1995) Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Seminars in Hematology, 32, 45-59.
[8] Kyle, R.A. and Greipp, P.R. (1983) Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clinic Proceedings, 58, 665-683.
[9] Kyle, R.A. and Bayrd, E.D. (1975) Amyloidosis: Review of 236 cases. Medicine (Baltimore), 54, 271-299. doi:10.1097/00005792-197507000-00001
[10] Kyle, R.A. and Bayrd, E.D. (1961) Primary systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. Archives of Internal Medicine, 107, 344-353. doi:10.1001/archinte.1961.03620030032004
[11] Austin, B.A., Duffy, B., Tan, C., Rodriguez, E.R., Starling, R.C. and Desai, M.Y. (2009) Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-bopsy proven cardiac amyloidosis. American Journal of Cardiology, 103, 1429-1433. doi:10.1016/j.amjcard.2009.01.361
[12] Cueto-Garcia, L., Reeder, G.S., Kyle, R.A., Wood, D.L., Seward, J.B., Naessens, J., Offord, K.P., Greipp, P.R., Edwards, W.D. and Tajik, A.J. (1985) Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival. Journal of the American College of Cardiology, 6, 737-743. doi:10.1016/S0735-1097(85)80475-7
[13] Koyama, J., Ray-Sequin, P.A. and Falk, R.H. (2002) Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation, 106, 556-561. doi:10.1161/01.CIR.0000023530.86718.B0
[14] Kristen, A.V., Perz, J.B., Schonland, S.O., Hegenbart, U., Schnabel, P.A., Kristen, J.H., Goldschmidt, H., Katus, H. A. and Dengler, T.J. (2007) Non-invasive predictors of survival in cardiac amyloidosis. European Journal of Heart Failure, 9, 617-624. doi:10.1016/j.ejheart.2007.01.012
[15] Mohty, D., Pibarot, P., Dumesnil, J.G., Darodes, N., Lavergne, D., Echahidi, N., Virot, P., Bordessoule, D. and Jaccard, A. (2011) Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Archives of Cardiovascular Diseases, 104, 611-618. doi:10.1016/j.acvd.2011.10.004
[16] Kapoor, P., Thenappan, T., Singh, E., Kumar, S. and Greipp, P.R. (2011) Cardiac amyloidosis: A practical approach to diagnosis and management. American Journal of Medicine, 124, 1006-1015. doi:10.1016/j.amjmed.2011.04.013
[17] Patel, A.R., Dubrey, S.W., Mendes, L.A., Skinner, M., Cupples, A., Falk, R.H. and Davidoff, R. (1997) Right ventricular dilation in primary amyloidosis: An independent predictor of survival. American Journal of Cardiology, 80, 486-492. doi:10.1016/S0002-9149(97)00400-1
[18] Rahman, J.E., Helou, E.F., Gelzer-Bell, R., Thompson, R. E., Kuo, C., Rodriguez, E.R., Hare, J.M., Baughman, K. L. and Kasper, E.K. (2004) Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. Journal of the American College of Cardiology, 43, 410-415. doi:10.1016/j.jacc.2003.08.043
[19] Piper, C., Butz, T., Farr, M., Faber, L., Oldenburg, O. and Horstkotte, D. (2010) How to diagnose cardiac amyloidosis early: Impact of ECG, tissue Doppler echocardiography, and myocardial biopsy. Amyloid, 17, 1-9. doi:10.3109/13506121003619310
[20] Murtagh, B., Hammill, S.C., Gertz, M.A., Kyle, R.A., Tajik, A.J. and Grogan, M. (2005) Electrocardiographic findings in primary systemic amyloidosis and biopsyproven cardiac involvement. American Journal of Cardiology, 95, 535-537. doi:10.1016/j.amjcard.2004.10.028
[21] Bellenger, N.G., Burgess, M.I., Ray, S.G., Lahiri, A., Coats, A.J., Cleland, J.G. and Pennell, D.J. (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? European Heart Journal, 21, 1387- 1396. doi:10.1053/euhj.2000.2011
[22] Jones, R.C., Francis, G.S. and Lauer, M.S. (2004) Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. Journal of the American College of Cardiology, 44, 1025-1029. doi:10.1016/j.jacc.2004.05.077
[23] Pocock, S.J., Wang, D., Pfeffer, M.A., Yusuf, S., McMurray, J.J., Swedberg, K.B., Ostergren, J., Michelson, E.L., Pieper, K.S. and Granger, C.B. (2006) Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal, 27, 65-75. doi:10.1093/eurheartj/ehi555
[24] Carroll, J.D., Gaasch, W.H. and McAdam, K.P. (1982) Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relation. American Journal of Cardiology, 49, 9-13. doi:10.1016/0002-9149(82)90270-3
[25] Selvanayagam, J.B., Hawkins, P.N., Paul, B., Myerson, S. G. and Neubauer, S. (2007) Evaluation and management of the cardiac amyloidosis. American Journal of Cardiology, 50, 2101-2110. doi:10.1016/j.jacc.2007.08.028

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.